The aim of the present study was to determine if prednisone, a glucocorticoid, added to conventional treatment for patients with decompensated congestive heart failure (DCHF) refractory to the conventional care, results in significant relief of congestive symptoms and improvement of clinical status.
DECOMPENSATED congestive heart failure (DCHF) is the most common cause of hospitalization among patients with congestive heart failure. It results from new onset of left ventricular systolic dysfunction or, more often, exacerbation of chronic heart failure. 1) Over the past decade, many advances in the management of DCHF have been achieved. However, the overall outcome remains discouraging. The predominant symptoms in such patients are dyspnea, fatigue and dependent edema, which are associated with pulmonary venous congestion, raised venous pressure, and low cardiac output. Accordingly, the rapid relief of symptoms achieved by intravenous administration of diuretics, vasodilators, and positive inotropic agents to decrease cardiac filling pressures and increase cardiac output remains the primary goal. 2) Prednisone, a glucocorticoid that has renal specific vasodilator properties, can increase renal plasma flow and glomerular filtration rate (GFR) with no changes in glomerular filtration fraction. [3] [4] [5] In addition, glucocorticoids may have important regulatory effects on natriuretic peptides and their receptors. In previous studies, we found that prednisone had potent diuretic effects in patients with stable congestive heart failure, and could restore renal function and elicit potent diuretic effects even in heart failure patients with refractory diuretic resistance. [6] [7] [8] Thus, prednisone may be a new drug candidate for patients with DCHF.
Therefore, we designed this perspective, nonplacebo controlled, observational study to determine the clinical efficacy of prednisone in the management of patients with decompensated congestive heart failure who were refractory to conventional treatment.
METHODS
Patients were included if they had orthopnea and refractory edema due to acute DCHF that was severe and had been hospitalized for at least 1 week and undergone intravenous therapy in addition to diuretics. A cardiac etiology for dyspnea was established based on history, coronary arteriography, and echocardiography, and the patients must have had at least two of the following: jugular venous distention, paroxysmal nocturnal dyspnea or 2-pillow orthopnea within 7 days before study entry, abdominal discomfort due to mesenteric congestion, and a chest X-ray film consistent with decompensated CHF. Prior to enrollment, all patients received furosemide, morphine, oral nitroglycerin, and oxygen but failed to response favorably. Patients may have had acute decompensation of chronic heart failure, gradual worsening of chronic heart failure, or new onset of acutely decompensated CHF. Patients who were receiving dobutamine or dopamine but who otherwise met entry criteria were also permitted to participate in the study. Patients with decompensated CHF in the setting of acute coronary syndromes, preserved systolic function, or renal failure were not excluded based on these conditions alone. The exclusion criteria were the following: patients with any signs of infection or any conditions that would contraindicate glucocorticoids; systolic blood pressure lower than 80 mm Hg or higher than 140 mmHg; cardiogenic shock; volume depletion; mechanical ventilation; hypertrophic or restric-Vol 49 No 5 tive cardiomyopathy; constrictive pericarditis, pulmonary arterial hypertension, or active myocarditis.
The study was conducted according to ethical principles stated in the Declaration of Helsinki (1996) and in adherence to local guidelines for good clinical practice. The protocol was approved by a local institutional ethics review committee, and written informed consent was obtained from all patients.
Prednisone (1 mg/kg/day with a maximum dose of 60 mg/day was given for at least 9 days) was added after written consent was obtained. Study endpoints: Primary endpoints were the effects on daily urine volume, patient assessed dyspnea and physician assessed global clinical status on day 1, day 2, day 3, day 4, and day 9, and changes in renal function such as glomerular filtration rate (GFR), fractional excretion of sodium (FENa), serum creatinine, and blood uric acid. Secondary endpoint was the overall safety profile. Selfassessed dyspnea and global clinical status consisted of 7-point categorical responses of the patients: Markedly improved (3); moderately improved (2); mildly improved (1); no change (0); minimally worsened (-1); moderately worsened (-2); and markedly worsened (-3). Statistical analysis: Continuous variables are expressed as the mean ± standard deviation (SD) unless otherwise stated. We treated long ordinal scales (eg, selfassessed dyspnea and global clinical status) as continuous data. All statistical tests were performed with two-sided alternatives and with a type I error of 0.05. SPSS software (version 13.0) was used.
RESULTS
Thirty-five patients were enrolled at our hospital between October 2005 and January 2007. The patient characteristics at the time of enrollment and medications received by the patients in the first 24 hours are shown in Table I . Figure 1 depicts the changes in daily urine volume, while Figure 2 shows the changes in patient assessed dyspnea and global clinical status over the study period. It was found that the patients' congestive symptoms and global clinical status improved with time, and there was a significant improvement in congestive symptoms and global clinical status after 3-day treatment, which was consistent with the changes in daily urine volume. At the end of the study, patient assessed dyspnea was markedly improved in 80% of DCHF patients (P < 0.01), while global clinical status was markedly improved in 68.6% of DCHF patients at the end of the study (P < 0.001). As a result, all but one patient discontinued IV therapies (ie, IV diuretics, IV inotropes, and IV nitroglycerine), and 33 patients (94% versus 54.3% at baseline, P < 0.01) were put on beta-blockers.
The effects of prednisone on hemodynamics and renal function are shown in Table II . Prednisone had no impact on serum sodium, potassium, chloride, or BUN. However, significantly increased GFR (calculated by modified CockroftGault formula) and FENa were observed. Consequently, serum creatinine and uric acid dropped dramatically. At the end of the study, 34 patients achieved weight loss and only 1 patient stayed unchanged. Overall, the average weight loss was 3.17 ± 2.10 kg (P < 0.01). With respect to safety profile, administration of prednisone for a relatively short period was safe and no severe side effects such as exacerbation of angina, infection, or poorly controlled hypertension were observed in the study period. Prednisone significantly increased the fasting glucose level in patients with diabetes (9.65 ± 0.75 mol/L at baseline versus 12.57 ± 0.57 mol/L after treatment, P < 0.01), however, it could be controlled by administering insulin. On the other hand, prednisone had no impact on patients without diabetes (4.91 ± 0.48 mol/L at baseline versus 4.98 ± 0.62 mol/L after treatment). 
DISCUSSION
To the best of our knowledge, this was the first study to determine the efficacy of prednisone in the management of patients with DCHF who were refractory to conventional treatment. Adding prednisone to the usual care resulted in a significant relief of the congestive symptoms and a dramatic improvement of clinical status accompanied by a potent diuresis and an improvement in renal function.
The congestive symptoms of heart failure are primarily due to fluid retention, which results from abnormal hemodynamic and neurohormonal system activation. The potential detrimental effects of fluid overload include an increase in ventricle wall stress, decrease in coronary perfusion, and worsening of mitral and tricuspid regurgitation as a result of ventricle spherical dilation. 9) These detrimental effects lead to further neurohormonal and renin-angiotensin-aldosterone system (RAAS) activation. Therefore, correction of fluid overload has been the mainstay of therapy for DCHF patients over the past several decades, because it can relieve the congestive symptoms rapidly and may improve long-term clinical outcomes such as rehospitalization and mortality. 10, 11) Currently, the most commonly used diuretics in clinical practice are loop diuretics such as furosemide and B-type natriuretic peptide (BNP). 12) So far, loop diuretics (ie, furosemide, torsemide, ethacrynic acid, and bumetanide) are the mainstays of correction of fluid overload in patients with DCHF. These drugs inhibit sodium and chloride reabsorption in the ascending limb of the loop of Henle. Loop diuretics may promote potent diuresis, however, at the expense of worsening of renal function, and patients may become refractory to them. 13) Furthermore, it is well recognized that furosemide, the most often used loop diuretic, may cause transient hemodynamic abnormalities and active RAAS. Administration of large doses of furosemide leads to a series of hemodynamic changes, which consist of a slight increase in heart rate, an increase in systemic vascular resistance, a slight reduction in stroke volume, and transient increases in filling pressure and right atrial pressure. 14) These untoward effects can only be mitigated by adequate diuresis. Data from registries and post hoc analysis of clinical trials show that loop diuretics may, at times, be harmful for patients with congestive heart failure. The ADHERE registry indicated that intravenous administration of diuretics resulted in an increase in-hospital mortality, a longer total length of stay, and a longer length of stay in the intensive care unit compared to patients who did not receive intravenous diuretics, even after adjusting for other prognostic factors. 15) In the absence of an effective therapy for patients with DCHF, human recombinant natriuretic peptides have been developed and tested in clinical trials. In a physiological setting, natriuretic peptides can induce potent diuresis and natriuresis accompanied by vasodilatation, with a resultant reduction in blood pressure and cardiac filling pressure and an increase in cardiac output. However, its favorable response is quantitatively smaller in heart failure patients than in normal subjects and appears to be blunted in patients with severe heart failure. 16) Despite its nomenclature as a "natriuretic" peptide, B-type natriuretic peptide (BNP) has not been observed with potent diuresis in most heart failure studies. Such a phenomenon is termed natriuretic peptide resistance. 17) Two meta-analyses trying to determine the efficacy of BNP in the management of DCHF found that it may worsen renal function and increase mortality. 18, 19) Overall, the correction of fluid overload, as the primary goal in the treatment of DCHF, is often not achieved. Diuretic-based strategies are not always effective in eliciting diuresis even with loop diuretics and BNP. In ADHERE, 21% of patients admitted for DCHF were discharged without weight loss or with a gain in weight. Thus, new therapeutic drugs with potent diuretic and renal protection properties are needed.
In the management of patients with congestive heart failure in our clinical practice, we have found that prednisone has potent diuretic effects and could improve renal function at the same time. There are several candidate mechanisms. First, glucocorticoids may enhance renal nitric oxide and prostacyclin production, [20] [21] [22] and thus specifically dilate renal vasculature. Also, glucocorticoids may promote natriuretic peptide excretion and upregulate their receptors in kidney, thus demonstrating a natriuretic peptide sensitizer-like effect. 6, 8) However, a drawback is that diuresis induced by prednisone is time-dependent, ie, there is, usually a lag time of 3 days for prednisone, as we described previously, before its effects are exerted in patients with heart failure. Of note, adding prednisone to conventional care resulted in reductions in serum creatinine and uric acid, and slight increases in BUN. This discrepancy may be a result of a relative hypovolemia secondary to potent diuresis induced by prednisone. In the present pilot study, the data suggest that prednisone may be of potential value in the management of DCHF.
Limitations of this study include the lack of a control group, the relatively small sample size, the relatively short period of observation, and the heterogeneity of etiology in the study population.
In conclusion, the data showed that adding prednisone to conventional treatment resulted in significant relief of the congestive symptoms, which was accompanied by a potent diuresis and an improvement in renal function. Additional studies to clarify the mechanisms in animal models and verify its clinical efficacy in a large randomized clinical trial are currently underway.
